Logo image of ACET

ADICET BIO INC (ACET) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ACET - US0070021086 - Common Stock

8.42 USD
+0.49 (+6.18%)
Last: 12/31/2025, 8:00:01 PM
8.4362 USD
+0.02 (+0.19%)
After Hours: 12/31/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, ACET scores 3 out of 10 in our fundamental rating. ACET was compared to 530 industry peers in the Biotechnology industry. ACET has a great financial health rating, but its profitability evaluates not so good. ACET has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ACET has reported negative net income.
In the past year ACET has reported a negative cash flow from operations.
ACET had negative earnings in each of the past 5 years.
In the past 5 years ACET always reported negative operating cash flow.
ACET Yearly Net Income VS EBIT VS OCF VS FCFACET Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

ACET has a Return On Assets of -72.53%. This is in the lower half of the industry: ACET underperforms 63.21% of its industry peers.
ACET has a Return On Equity (-88.63%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -72.53%
ROE -88.63%
ROIC N/A
ROA(3y)-47.68%
ROA(5y)-37.04%
ROE(3y)-56.8%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
ACET Yearly ROA, ROE, ROICACET Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACET so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACET Yearly Profit, Operating, Gross MarginsACET Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ACET has been increased compared to 1 year ago.
The number of shares outstanding for ACET has been increased compared to 5 years ago.
ACET has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACET Yearly Shares OutstandingACET Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ACET Yearly Total Debt VS Total AssetsACET Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ACET has an Altman-Z score of 19.64. This indicates that ACET is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ACET (19.64) is better than 89.25% of its industry peers.
There is no outstanding debt for ACET. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.64
ROIC/WACCN/A
WACCN/A
ACET Yearly LT Debt VS Equity VS FCFACET Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ACET has a Current Ratio of 7.48. This indicates that ACET is financially healthy and has no problem in meeting its short term obligations.
ACET has a better Current ratio (7.48) than 72.83% of its industry peers.
A Quick Ratio of 7.48 indicates that ACET has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.48, ACET is in the better half of the industry, outperforming 73.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.48
Quick Ratio 7.48
ACET Yearly Current Assets VS Current LiabilitesACET Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.32% over the past year.
EPS 1Y (TTM)26.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.93% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.14%
EPS Next 2Y17.62%
EPS Next 3Y10.39%
EPS Next 5Y15.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACET Yearly Revenue VS EstimatesACET Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2028 2029 2030 2031 2032 50M 100M 150M 200M
ACET Yearly EPS VS EstimatesACET Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACET. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACET. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACET Price Earnings VS Forward Price EarningsACET Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACET Per share dataACET EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.62%
EPS Next 3Y10.39%

More info and screens

0

5. Dividend

5.1 Amount

ACET does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ADICET BIO INC

NASDAQ:ACET (12/31/2025, 8:00:01 PM)

After market: 8.4362 +0.02 (+0.19%)

8.42

+0.49 (+6.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners25.62%
Inst Owner Change-0.51%
Ins Owners0.2%
Ins Owner Change0%
Market Cap1.29B
Revenue(TTM)N/A
Net Income(TTM)-118.20M
Analysts84.29
Price Target7.75 (-7.96%)
Short Float %11.01%
Short Ratio6.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.59%
Min EPS beat(2)-9.54%
Max EPS beat(2)8.37%
EPS beat(4)3
Avg EPS beat(4)3.58%
Min EPS beat(4)-9.54%
Max EPS beat(4)13.38%
EPS beat(8)6
Avg EPS beat(8)-1.85%
EPS beat(12)7
Avg EPS beat(12)-14.75%
EPS beat(16)9
Avg EPS beat(16)-3.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)35.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.01%
EPS NY rev (1m)0.65%
EPS NY rev (3m)8.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.68
P/tB 9.68
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -72.53%
ROE -88.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.68%
ROA(5y)-37.04%
ROE(3y)-56.8%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.48
Quick Ratio 7.48
Altman-Z 19.64
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)246.96%
Cap/Depr(5y)333.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.71%
EPS Next Y16.14%
EPS Next 2Y17.62%
EPS Next 3Y10.39%
EPS Next 5Y15.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.88%
OCF growth 3YN/A
OCF growth 5YN/A

ADICET BIO INC / ACET FAQ

What is the fundamental rating for ACET stock?

ChartMill assigns a fundamental rating of 3 / 10 to ACET.


Can you provide the valuation status for ADICET BIO INC?

ChartMill assigns a valuation rating of 0 / 10 to ADICET BIO INC (ACET). This can be considered as Overvalued.


Can you provide the profitability details for ADICET BIO INC?

ADICET BIO INC (ACET) has a profitability rating of 0 / 10.


How financially healthy is ADICET BIO INC?

The financial health rating of ADICET BIO INC (ACET) is 8 / 10.


What is the expected EPS growth for ADICET BIO INC (ACET) stock?

The Earnings per Share (EPS) of ADICET BIO INC (ACET) is expected to grow by 16.14% in the next year.